Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Extraction of Aerosol-Deposited Yersinia pestis from Indoor Surfaces To Determine Bacterial Environmental Decay.

Gut IM, Bartlett RA, Yeager JJ, Leroux B, Ratnesar-Shumate S, Dabisch P, Karaolis DKR.

Appl Environ Microbiol. 2016 Apr 18;82(9):2809-2818. doi: 10.1128/AEM.03989-15. Print 2016 May.

2.

Complete Genome Sequence of the Quality Control Strain Staphylococcus aureus subsp. aureus ATCC 25923.

Treangen TJ, Maybank RA, Enke S, Friss MB, Diviak LF, Karaolis DK, Koren S, Ondov B, Phillippy AM, Bergman NH, Rosovitz MJ.

Genome Announc. 2014 Nov 6;2(6). pii: e01110-14. doi: 10.1128/genomeA.01110-14.

3.

STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer.

Chandra D, Quispe-Tintaya W, Jahangir A, Asafu-Adjei D, Ramos I, Sintim HO, Zhou J, Hayakawa Y, Karaolis DK, Gravekamp C.

Cancer Immunol Res. 2014 Sep;2(9):901-10. doi: 10.1158/2326-6066.CIR-13-0123. Epub 2014 Jun 9.

4.

c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection.

Hu DL, Narita K, Hyodo M, Hayakawa Y, Nakane A, Karaolis DK.

Vaccine. 2009 Jul 30;27(35):4867-73. doi: 10.1016/j.vaccine.2009.04.053. Epub 2009 May 9.

PMID:
19406185
5.

c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection.

Ogunniyi AD, Paton JC, Kirby AC, McCullers JA, Cook J, Hyodo M, Hayakawa Y, Karaolis DK.

Vaccine. 2008 Aug 26;26(36):4676-85. doi: 10.1016/j.vaccine.2008.06.099. Epub 2008 Jul 18.

6.

Cyclic di-GMP stimulates protective innate immunity in bacterial pneumonia.

Karaolis DK, Newstead MW, Zeng X, Hyodo M, Hayakawa Y, Bhan U, Liang H, Standiford TJ.

Infect Immun. 2007 Oct;75(10):4942-50. Epub 2007 Jul 23.

7.

Bacterial c-di-GMP is an immunostimulatory molecule.

Karaolis DK, Means TK, Yang D, Takahashi M, Yoshimura T, Muraille E, Philpott D, Schroeder JT, Hyodo M, Hayakawa Y, Talbot BG, Brouillette E, Malouin F.

J Immunol. 2007 Feb 15;178(4):2171-81.

8.

Chemical behavior of bis(3'-5')diguanylic acid in aqueous solutions.

Hyodo M, Sato Y, Hayakawa Y, Karaolis DK.

Nucleic Acids Symp Ser (Oxf). 2005;(49):117-8.

PMID:
17150661
9.

3',5'-cyclic diguanylic acid reduces the virulence of biofilm-forming Staphylococcus aureus strains in a mouse model of mastitis infection.

Brouillette E, Hyodo M, Hayakawa Y, Karaolis DK, Malouin F.

Antimicrob Agents Chemother. 2005 Aug;49(8):3109-13.

10.

c-di-GMP (3'-5'-cyclic diguanylic acid) inhibits Staphylococcus aureus cell-cell interactions and biofilm formation.

Karaolis DK, Rashid MH, Chythanya R, Luo W, Hyodo M, Hayakawa Y.

Antimicrob Agents Chemother. 2005 Mar;49(3):1029-38.

11.

3',5'-Cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation.

Karaolis DK, Cheng K, Lipsky M, Elnabawi A, Catalano J, Hyodo M, Hayakawa Y, Raufman JP.

Biochem Biophys Res Commun. 2005 Apr 1;329(1):40-5.

PMID:
15721270
12.

Genetic diversity and antibiotic resistance of clinical and environmental Vibrio Cholerae suggests that many serogroups are reservoirs of resistance.

Campos LC, Zahner V, Avelar KE, Alves RM, Pereira DS, Vital BJ, Freitas FS, Salles CA, Karaolis DK.

Epidemiol Infect. 2004 Oct;132(5):985-92.

13.
14.

Role of exopolysaccharide, the rugose phenotype and VpsR in the pathogenesis of epidemic Vibrio cholerae.

Rashid MH, Rajanna C, Zhang D, Pasquale V, Magder LS, Ali A, Dumontet S, Karaolis DK.

FEMS Microbiol Lett. 2004 Jan 15;230(1):105-13.

15.

The vibrio pathogenicity island of epidemic Vibrio cholerae forms precise extrachromosomal circular excision products.

Rajanna C, Wang J, Zhang D, Xu Z, Ali A, Hou YM, Karaolis DK.

J Bacteriol. 2003 Dec;185(23):6893-901.

16.

Identification of genes involved in the switch between the smooth and rugose phenotypes of Vibrio cholerae.

Rashid MH, Rajanna C, Ali A, Karaolis DK.

FEMS Microbiol Lett. 2003 Oct 10;227(1):113-9.

17.
18.
19.

High-frequency rugose exopolysaccharide production by Vibrio cholerae.

Ali A, Rashid MH, Karaolis DK.

Appl Environ Microbiol. 2002 Nov;68(11):5773-8.

20.

Prevalence of virulence-associated genes in clinical and environmental Vibrio cholerae strains isolated in Brazil between 1991 and 1999.

Vital Brazil JM, Alves RM, Rivera IN, Rodrigues DP, Karaolis DK, Campos LC.

FEMS Microbiol Lett. 2002 Sep 24;215(1):15-21.

21.

Comparison of Vibrio cholerae pathogenicity islands in sixth and seventh pandemic strains.

Karaolis DK, Lan R, Kaper JB, Reeves PR.

Infect Immun. 2001 Mar;69(3):1947-52.

22.

Vibrio cholerae TCP: a trifunctional virulence factor?: Response.

Karaolis DK, Kaper JB.

Trends Microbiol. 1999 Oct;7(10):393. No abstract available.

PMID:
10498944
23.

A bacteriophage encoding a pathogenicity island, a type-IV pilus and a phage receptor in cholera bacteria.

Karaolis DK, Somara S, Maneval DR Jr, Johnson JA, Kaper JB.

Nature. 1999 May 27;399(6734):375-9.

PMID:
10360577
24.

A Vibrio cholerae pathogenicity island associated with epidemic and pandemic strains.

Karaolis DK, Johnson JA, Bailey CC, Boedeker EC, Kaper JB, Reeves PR.

Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3134-9.

26.

Cloning of the RDEC-1 locus of enterocyte effacement (LEE) and functional analysis of the phenotype on HEp-2 cells.

Karaolis DK, McDaniel TK, Kaper JB, Boedeker EC.

Adv Exp Med Biol. 1997;412:241-5.

PMID:
9192020
29.

Supplemental Content

Loading ...
Support Center